Skip to content

Tralokinumab

Interleukin-13 Antagonist — DERMATOLOGICALS

Also known as: adbry, adtralza, CAT-354

EMA approvedFDA approvedPMDA approvedATC D11AH07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Tralokinumab is a drug in the Interleukin-13 Antagonist class catalogued in DrugCentral. It was first approved by the EMA in 2021. Its mechanism of action is classified as Interleukin-13 Antagonists. DrugCentral lists 1 molecular target, including IL13. Recorded indications include Moderate to severe atopic dermatitis.

  • Drug class: Interleukin-13 Antagonist.
  • Mechanism of action: Interleukin-13 Antagonists.
  • Molecular targets: IL13 (1 listed in DrugCentral).
  • Indications: Moderate to severe atopic dermatitis.
  • ATC code: D11AH07 (Agents for dermatitis, excluding corticosteroids).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Moderate to severe atopic dermatitis

Mechanism & targets

Mechanism of action (MoA)Interleukin-13 Antagonists
Established pharmacologic classInterleukin-13 Antagonist

Molecular targets (1)

TargetGeneActionActivity
Interleukin-13IL13otherKd 10.22

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2022-12-23PMDA—Leo Pharma K.K.
2021-12-27FDA—LEO PHARMA AS
2021-07-16EMA—LEO PHARMA A/S

ATC classification

ATC codeTherapeutic hierarchy
D11AH07DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Agents for dermatitis, excluding corticosteroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Pruritus653.5
Drug ineffective438.0
Eczema405.8
Dry skin399.4
Dermatitis atopic373.4
Conjunctivitis296.1
Injection site pain280.9
Rash277.3
Eye pruritus275.9
Ocular hyperaemia264.7
Skin exfoliation231.0
Injection site pruritus227.6

Chemical structure

Molecular formula—
Molecular weight—
CAS number1044515-88-9
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tralokinumab used for?

DrugCentral lists the following indications for Tralokinumab: Moderate to severe atopic dermatitis.

How does Tralokinumab work?

Tralokinumab is classified as Interleukin-13 Antagonists; its molecular targets in DrugCentral include IL13.

When was Tralokinumab first approved?

Tralokinumab was first approved by the EMA in 2021.

What drug class does Tralokinumab belong to?

Tralokinumab is in the Interleukin-13 Antagonist class.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2021-07-16
AgencyEMA
Targets1
Indications1
Formula—
DrugCentral ID5479
Interactive profile